Matthew Reilley headshot

Matthew James Reilley

Assistant Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Brown Medical School, MD
Residency, University of Pennsylvania
Fellowship, University of Texas MD Anderson Cancer Center

Dr. Reilley earned his medical degree from Brown University. He completed his internal medicine residency at the University of Pennsylvania and a fellowship in hematology & medical oncology at The University of Texas MD Anderson Cancer Center. Dr. Reilley is board certified in internal medicine.

Dr. Reilley manages patients with gastrointestinal cancers, including esophageal, gastric, duodenal, ampullary, biliary, hepatocellular, pancreatic, colon and rectal. He has research interests in developmental therapeutics, tumor immunobiology, colon cancer and improving clinical trial access.

During his fellowship at MD Anderson Cancer Center, Dr. Reilley was recognized as Chief Fellow and was a T32 Training Grant Awardee. He also received the Society for Translational Oncology’s Rising Star in Oncology Award and the American Society for Clinical Oncology’s Annual Meeting Merit Award, presented in recognition of high-quality research.

In his spare time, Dr. Reilley enjoys reading, running and spending time outdoors with his wife and two sons.

A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
Source: Surface Oncology, Inc.
May 07, 2021 – May 06, 2024
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Source: ICON Clinical Research, LLC
May 16, 2019 – May 15, 2023
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Source: Xencor, Inc.
May 11, 2018 – May 10, 2023
MD-INMD-HO - Reilley - Adlai Noryte An Open-Label Multicenter Phase Ib Study of AN0025 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Source: Syneos Health, LLC
March 17, 2020 – March 16, 2023
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Source: NRG Oncology Foundation, Inc.
March 02, 2020 – March 01, 2023
MD-INMD-HO - Reilley - Deciphera - DCC-2818-03-002
Source: Deciphera Pharmaceuticals, LLC
February 04, 2019 – February 03, 2023
MD-INMD-HO - Reilley - Seattle Genetics - SGNTV-001
Source: Seattle Genetics, Inc.
January 04, 2019 – January 03, 2023
MD-INMD-HO - Reilley - MedImmune 9447
Source: MedImmune, LLC
September 24, 2018 – September 23, 2022
LCCC 1717: Phase II single-arm study of the combination of palbociclib and cetuximab in KRAS/NRAS/BRAF wild-type metastatic colorectal cancer
Source: University of North Carolina at Chapel Hill
September 04, 2018 – September 03, 2022
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
Source: Xencor, Inc.
August 27, 2018 – August 26, 2022
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Source: Exact Sciences Corporation
November 27, 2018 – July 07, 2020